1.25mg Semaglutide: What This Dose Is — and What It Isn't

You've seen '1.25mg semaglutide' somewhere, here's where it came from

Picture this: you're a few weeks into researching Wegovy online, tabs multiplying, and you come across a forum post or an older article mentioning 1.25mg semaglutide. It sounds plausible, close to the 1.0mg Wegovy step, just a fraction higher. So you search it, and the results are a mix of diabetes prescribing guides, US content and genuine confusion.

The 1.25mg figure has roots in the Ozempic diabetes prescribing schedule. In some countries and in earlier clinical use, 1.25mg appeared as an interim titration step for type 2 diabetes management, something that never carried over into the Wegovy weight-management programme. It is not a dose you would encounter on a UK private prescription for weight loss today.

Ozempic and Wegovy both contain semaglutide, but they carry separate UK marketing authorisations. Semaglutide's licensed uses in the UK differ significantly depending on the brand and indication. The MHRA licenses them individually, and prescribing for weight loss should follow the Wegovy schedule, full stop. If you're reading about 1.25mg in a weight-loss context, that content is either outdated, written for a different market, or drawn from the diabetes literature.

It's worth knowing this, because dose confusion can lead people to under-dose (and see weaker results) or to seek products outside the licensed supply chain.

The five Wegovy steps, and what each one is actually for

The licensed Wegovy titration in the UK moves in deliberate increments: 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg, with roughly four weeks at each level before stepping up. The STEP 1 clinical trial, published in the New England Journal of Medicine, used this schedule and recorded an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose.

The early doses (0.25mg and 0.5mg) are there primarily to let your digestive system adjust. Nausea and other gastrointestinal symptoms are most common at the start and after each step-up; a slower climb tends to make them shorter-lived and milder. Most people find that by the time they reach 1.0mg, things have settled considerably.

The 1.0mg step sits in the middle of the ladder, and for some patients it remains the highest tolerated dose if side effects are persistent. A prescriber won't push you to 1.7mg or 2.4mg simply because the schedule allows it, the right maintenance dose is the highest one you tolerate well, not automatically the maximum. You can read more about what to expect at the 1mg dose and how the titration decision is made.

One practical note on 2.4mg: as of 14 April 2026, the MHRA also approved a higher 7.2mg Wegovy pen for adults with a BMI of 30 or above. This approval extended the upper end of the schedule, though the starting point and titration approach remain the same. Details are confirmed at the prescribing stage.

Ozempic vs Wegovy: same molecule, different purpose

This is probably the most important distinction on this page. Both Ozempic and Wegovy contain semaglutide, but their licensed uses, dose schedules and regulatory positions in the UK are not interchangeable.

Ozempic is licensed for type 2 diabetes, not weight management. Using it for weight loss is off-label, and the MHRA has been clear that GLP-1 medicines should not be positioned as quick or cosmetic weight-loss tools. The NHS semaglutide medicines page covers both products and the distinction between them, and it's a useful resource if you want the detail from an official source: see the NHS guidance on semaglutide.

The 1.25mg figure you've encountered almost certainly comes from the Ozempic or older clinical literature. There's no equivalent step in the Wegovy weight-management schedule, and a UK prescriber treating you for weight loss wouldn't reach for that number.

If someone is offering you 1.25mg semaglutide labelled as a weight-loss product, that's a red flag worth taking seriously. Medicines sourced outside the licensed UK supply chain (particularly those sold without a clinical assessment) carry real risks, including contamination and incorrect dosing. The MHRA has warned repeatedly about counterfeit weight-loss injectable products circulating online. Report anything suspicious at the MHRA Yellow Card site.

What this means if you're considering semaglutide for weight management

If weight management is your goal, the relevant product is Wegovy, prescribed following a clinical assessment. Eligibility for private treatment generally requires a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, raised cholesterol or pre-diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. A prescriber makes the call on suitability after reviewing your full picture, BMI alone doesn't determine approval.

If cost is a factor in your thinking, our page on Wegovy pricing in the UK walks through what private treatment typically costs and what an all-in price should include. It's a useful read before you start comparing providers.

Some people also arrive at this question while on other medication, thyroid conditions, for example, raise separate questions about interactions. If that's relevant to your situation, our page on semaglutide and levothyroxine covers what the evidence says.

At nume (at our pharmacy) every consultation is read by a named GPhC-registered Independent Prescriber, and the same-day review means most people hear back the same afternoon, which is a lot easier to fit around a busy day than a GP appointment that takes weeks to land. Ready to speak to someone qualified? Speak to our prescribers through a free consultation whenever you're ready.